Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

3.130 +0.010 (+0.32%)

Streaming Delayed Price Updated: 1:27 PM EDT, May 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	12,022,496
Open	3.115
Bid (Size)	3.120 (592,800)
Ask (Size)	3.130 (305,300)
Prev. Close	3.120
Today's Range	3.110 - 3.130
52wk Range	0.6925 - 4.175
Shares Outstanding	28,277,493
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders

May 05, 2026

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq -

May 05, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Performance

YTD	-15.6%	-15.6%
1 Month	+19.9%	+19.9%
3 Month	-10.6%	-10.6%
6 Month	+6.1%	+6.1%
1 Year	+187.2%	+187.2%

More News

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

May 04, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Friday's session: most active stocks ↗

May 01, 2026

Via Chartmill

Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q4 2025 Results Amid Strategic Expansion ↗

March 10, 2026

Via Chartmill

What's going on in today's session ↗

May 01, 2026

Via Chartmill

Veeva Systems, Five9, AXT And Other Big Stocks Moving Higher On Friday ↗

May 01, 2026

Via Benzinga

Which stocks are moving on Friday? ↗

May 01, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

May 01, 2026

Via Chartmill

ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

May 01, 2026

From Halper Sadeh LLC

Via Business Wire

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 01, 2026

Via Chartmill

Esperion to be Acquired by ARCHIMED

May 01, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Report First Quarter 2026 Financial Results on May 7

April 23, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

April 02, 2026

From Athyrium Capital Management, LP

Via GlobeNewswire

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

April 02, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

March 31, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

March 30, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

March 17, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

March 16, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗

March 10, 2026

Via Stocktwits

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 10, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

March 03, 2026

From Corstasis Therapeutics Inc.

Via Business Wire

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

March 03, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

February 24, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Participate in The 2026 Citizens Life Sciences Conference

February 18, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Esperion Therapeutics, Inc. - Common Stock publicly traded?

Yes, Esperion Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Esperion Therapeutics, Inc. - Common Stock trade on?

Esperion Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Esperion Therapeutics, Inc. - Common Stock?

The ticker symbol for Esperion Therapeutics, Inc. - Common Stock is ESPR on the Nasdaq Stock Market

What is the current price of Esperion Therapeutics, Inc. - Common Stock?

The current price of Esperion Therapeutics, Inc. - Common Stock is 3.130

When was Esperion Therapeutics, Inc. - Common Stock last traded?

The last trade of Esperion Therapeutics, Inc. - Common Stock was at 05/06/26 01:27 PM ET

What is the market capitalization of Esperion Therapeutics, Inc. - Common Stock?

The market capitalization of Esperion Therapeutics, Inc. - Common Stock is 88.51M

How many shares of Esperion Therapeutics, Inc. - Common Stock are outstanding?

Esperion Therapeutics, Inc. - Common Stock has 89M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.